| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02466243 Details | 2023-01-19 Interventional | 2 | 22 | Lenabasum Dermatomyositis | Sponsor terminated open-label extension. - | |||
| NCT04433988 Details | 2023-01-18 Interventional | 1/2 | 0 | Pentoxifylline COVID | Institutional problems - | |||
| NCT02736149 Details | 2023-01-18 Interventional | 2 | 51 | Ubenimex Familial Primar… Hypertension Pulmonary Arter… | Following the failure to demonstrate efficacy in EIG-UBX-001, the sponsor decided to terminate
Study EIG-UBX-002. - | |||
| NCT04857840 Details | 2023-01-17 Interventional | 3 | 419 | Firibastat Hypertension Hypertension (H… | No Efficacy demonstrated inn the QGC001-3QG1 study - | |||
| NCT04575584 2020-003367-26 Details | 2023-01-17 Interventional | 2/3 | [1 Refs] | 304 | Molnupiravir COVID-19 Coronavirus Dis… | Business reasons - | ||
| NCT04383691 Details | 2023-01-17 Interventional | 3 | 124 | Lurasidone Hydr… Depression Depressive Diso… Bipolar I Depre… | Company's business decision - | |||
| NCT04479436 2019-004418-32 Details | 2023-01-13 Interventional | 2 | 40 | Patritumab deru… Colorectal Neop… Metastatic Colo… | Study was terminated early given the Interim Analysis for Part 1 (signal finding) did not meet
pre-specified criteria and will not proceed to Part 2. Sponsor will proceed closing the study. - | |||
| NCT04072601 Details | 2023-01-13 Interventional | 4 | [1 Refs] | 78 | Atorvastatin Disease Progres… Fibrosis Liver Cirrhosis Liver Cirrhoses | Study part one completed - | ||
| NCT03816488 Details | 2023-01-13 Interventional | 1 | 0 | Metformin Salicylsalicyli… Diabetes Mellit… Hyperglycemia Postoperative C… Perioperative/P… | Unable to source salsalate. - | |||
| NCT04969861 Details | 2023-01-12 Interventional | 2/3 | 1 | Pembrolizumab Head and Neck N… Recurrence Metastatic Head… Recurrent Head … | Nektar Therapeutics made the decision to discontinue the bempegaldesleukin program based on
three negative studies. SFJ Pharmaceuticals, Inc. and Nektar Therapeutics, in consultation with
the study IDMC, have decided to discontinue PROPEL-36. - | |||
| NCT02409238 Details | 2023-01-11 Interventional | 4 | 105 | Metformin Cognitive Dysfu… Diabetes Mellit… Diabetes Mellit… Insulin Resista… Mild Cognitive … | 1. Limits of grant funding reached
2. A/Prof Ng Tze Pin (P.I. & holder of NMRC Grant (CIRG12may033) funding this study) retired
in Aug 2022.
3. Resignations of staff and collaborators especially over the 1st 2 years of the COVID-19
pandemic - | |||
| NCT04248465 2019-004619-30 Details | 2023-01-10 Interventional | 3 | 382 | Ravulizumab Amyotrophic Lat… Motor Neuron Di… Sclerosis ALS | The IDMC recommended the study be discontinued due to lack of efficacy with ravulizumab. The IDMC recommended the study be discontinued due to lack of efficacy with ravulizumab. | |||
| NCT04154150 Details | 2023-01-10 Interventional | 4 | 16 | Ketamine Suicide Suicide, Attemp… | Midway through this pilot study, funding was obtained to support a much larger study of the
same interventions in this clinical population. Therefore the pilot study was halted so as not
to compete with enrollment for the larger study. Pilot study leading to small numbers of patients in each treatment arm. Descriptive statistics are reported without statistical analysis to directly compare groups, given the small number of patients within each group leading to low statistical power. | |||
| NCT02910843 Details | 2023-01-10 Interventional | 1 | 25 | Capecitabine Rectal Neoplasm… Rectal Cancer | due to structural financial deficit of SAKK - | |||
| NCT05580250 Details | 2023-01-09 Interventional | 1 | 0 | Metformin Simvastatin Healthy | The sponsor made a business decision to withdraw the trial. - | |||
| NCT05571111 Details | 2023-01-09 Interventional | 2 | 0 | Chorionic Gonad… Infertility | Based on company decision to close the project. No trial participants received any study drug. - | |||
| NCT04044430 Details | 2023-01-09 Interventional | 1 | 2 | Nivolumab Adenocarcinoma Colonic Neoplas… Colorectal Neop… Rectal Neoplasm… Metastatic Colo… Metastatic Colo… Metastatic Micr… Metastatic Rect… Stage III Colon… Stage III Color… Stage III Recta… Stage IIIA Colo… Stage IIIA Colo… Stage IIIA Rect… Stage IIIB Colo… Stage IIIB Colo… Stage IIIB Rect… Stage IIIC Colo… Stage IIIC Colo… Stage IIIC Rect… Stage IV Colon … Stage IV Colore… Stage IV Rectal… Stage IVA Colon… Stage IVA Color… Stage IVA Recta… Stage IVB Colon… Stage IVB Color… Stage IVB Recta… Stage IVC Colon… Stage IVC Color… Stage IVC Recta… | Sponsor funding - | |||
| NCT04775329 Details | 2023-01-06 Interventional | 2/3 | 2 | Rifaximin Blind Loop Synd… Peritonitis Decompensated C… Small Bowel Bac… | Slow recruitment and study closure - | |||
| NCT04249167 Details | 2023-01-06 Interventional | 1 | 0 | Albumin-Bound P… Antibodies, Mon… Atezolizumab Paclitaxel Breast Neoplasm… Carcinoma Triple Negative… Anatomic Stage … Anatomic Stage … Anatomic Stage … Anatomic Stage … Anatomic Stage … Locally Advance… Metastatic Trip… Prognostic Stag… Prognostic Stag… Prognostic Stag… Prognostic Stag… Prognostic Stag… | study was dropped - | |||
| NCT02393248 Details | 2023-01-06 Interventional | 1/2 | 201 | Docetaxel Gemcitabine Pembrolizumab Trastuzumab Cholangiocarcin… Endometrial Neo… Multiple Myelom… Myeloproliferat… Stomach Neoplas… Breast Cancer Endometrial Can… Gastric Cancer Lung Cancer MPN Myeloproliferat… Solid Tumor UC Urothelial Canc… | - - |